HAEMONETICS CORP — Director's Dealing 2019

May 24, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-05-22

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-22	Common Stock	A	53654	—	Acquired	274645	Direct
2019-05-23	Common Stock	S	24412	$99.39	Disposed	250233	Direct

Footnotes

F1: Represents shares earned from performance share unit awards granted to the reporting person on June 29, 2016 and July 26, 2017 with performance periods ending on March 30, 2019, based on achievement of 80.05% and 144.31% of their respective internal financial and performance metric targets, as certified by the Compensation Committee of the Board of Directors effective May 22, 2019.

F2: This number includes unvested restricted stock units previously reported.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the performance share units reported above. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.